Rhumbline Advisers Buys 3,529 Shares of Guardant Health, Inc. (NASDAQ:GH)

Rhumbline Advisers grew its stake in Guardant Health, Inc. (NASDAQ:GH) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,230 shares of the company’s stock after buying an additional 3,529 shares during the period. Rhumbline Advisers owned 0.14% of Guardant Health worth $5,109,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after acquiring an additional 6,618,785 shares in the last quarter. Eventide Asset Management LLC raised its stake in shares of Guardant Health by 2.0% during the third quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company’s stock worth $88,028,000 after acquiring an additional 76,762 shares in the last quarter. Geode Capital Management LLC lifted its position in Guardant Health by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after purchasing an additional 29,686 shares during the last quarter. ARK Investment Management LLC raised its position in Guardant Health by 233.5% during the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock valued at $34,701,000 after purchasing an additional 1,059,104 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock valued at $44,732,000 after purchasing an additional 238,037 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Down 2.5 %

Shares of NASDAQ GH opened at $42.11 on Friday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The firm has a market cap of $5.20 billion, a P/E ratio of -11.83 and a beta of 1.32. The business’s 50 day moving average price is $40.87 and its 200 day moving average price is $31.89.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. As a group, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on GH. JPMorgan Chase & Co. raised their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Piper Sandler boosted their price objective on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Barclays assumed coverage on Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price for the company. Canaccord Genuity Group increased their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Scotiabank lifted their target price on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday. Nineteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $48.21.

Insider Buying and Selling at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,768 shares of company stock worth $98,798 in the last three months. 5.50% of the stock is owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.